Loading...
Zelira Therapeutics Limited
ZLD.AX•ASX
Healthcare
Biotechnology
A$0.41
A$0.00(0.00%)
Zelira Therapeutics Limited (ZLD.AX) Financial Performance & Income Statement Overview
Review Zelira Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-68.47%
↓ 68.47%
Operating Income Growth
19.89%
↑ 19.89%
Net Income Growth
-556.18%
↓ 556.18%
Operating Cash Flow Growth
39.46%
↑ 39.46%
Operating Margin
-10876.80%
↓ 10876.80%
Gross Margin
-697.55%
↓ 697.55%
Net Profit Margin
-11849.86%
↓ 11849.86%
ROE
75.02%
↑ 75.02%
ROIC
56.33%
↑ 56.33%
Zelira Therapeutics Limited (ZLD.AX) Income Statement & Financial Overview
Review Zelira Therapeutics Limited's (ZLD.AX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $40229.00 | $54723.00 | $224172.00 | $76949.00 |
| Cost of Revenue | $323309.00 | $1.16M | $1.41M | $2.11M |
| Gross Profit | -$283080.00 | -$1.11M | -$1.18M | -$2.03M |
| Gross Profit Ratio | -$7.04 | -$20.19 | -$5.28 | -$26.42 |
| R&D Expenses | $1.57M | $1.24M | $787992.00 | $548436.00 |
| SG&A Expenses | $820034.00 | $910379.00 | $1.93M | $666024.00 |
| Operating Expenses | $2.55M | $2.23M | $2.73M | $1.47M |
| Total Costs & Expenses | $2.88M | $3.39M | $4.14M | $3.58M |
| Interest Income | $0.00 | $0.00 | $62.00 | $72.00 |
| Interest Expense | $528137.00 | $211135.00 | $44511.00 | $32149.00 |
| Depreciation & Amortization | $202564.00 | $276474.00 | $270750.00 | $274474.00 |
| EBITDA | -$2.61M | -$33.84M | -$3.43M | -$3.36M |
| EBITDA Ratio | -$64.78 | -$55.95 | -$16.25 | -$41.90 |
| Operating Income | -$2.83M | -$3.34M | -$3.91M | -$3.50M |
| Operating Income Ratio | -$70.47 | -$61.00 | -$17.46 | -$45.47 |
| Other Income/Expenses (Net) | -$501925.00 | -$30.98M | -$51173.00 | -$165884.00 |
| Income Before Tax | -$3.34M | -$34.32M | -$3.75M | -$3.66M |
| Income Before Tax Ratio | -$82.95 | -$627.21 | -$16.71 | -$47.63 |
| Income Tax Expense | -$919735.00 | -$187775.00 | -$1.14M | -$387423.00 |
| Net Income | -$2.43M | -$34.13M | -$2.30M | -$3.28M |
| Net Income Ratio | -$60.51 | -$623.78 | -$10.24 | -$42.59 |
| EPS | -$0.21 | -$3.01 | -$0.21 | -$0.34 |
| Diluted EPS | -$0.21 | -$3.01 | -$0.21 | -$0.34 |
| Weighted Avg Shares Outstanding | $11.35M | $11.35M | $10.86M | $9.58M |
| Weighted Avg Shares Outstanding (Diluted) | $11.35M | $11.35M | $10.86M | $9.58M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan